Rystiggo Drug Interactions: 219 Major, 38 Moderate
Rystiggo (Rozanolixizumab) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rystiggo. Always confirm against the full prescribing information.
100 interactions
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rozanolixizumab.
Level 2 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Rozanolixizumab.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Rozanolixizumab.
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rozanolixizumab.
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rozanolixizumab.
Level 2 evidence
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Rozanolixizumab.
Level 1 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Rozanolixizumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab.
Level 2 evidence
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Rozanolixizumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Amivantamab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Ansuvimab.
Level 2 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Rozanolixizumab.
Level 1 evidence
Enter your NPI to unlock 66 major interactions for Rystiggo
Rystiggo (Rozanolixizumab) has 379 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rystiggo (Rozanolixizumab) has 219 major, 38 moderate, and 122 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rystiggo. Always confirm against the full prescribing information.